Treatment of Latent Tuberculosis Infection

Introduction to LTBI Treatment

The European Respiratory Society recommends that treatment of latent tuberculosis infection (LTBI) is required for individuals at high risk of progression to active TB disease, as treatment reduces the lifetime risk of reactivation from 5-15% to near-zero with regimens that are 60-90% effective 1

The Centers for Disease Control and Prevention strongly recommends treatment for HIV-infected persons, who have a 5-10% annual reactivation risk 2, 3
The European Respiratory Society recommends treatment for recent contacts of infectious pulmonary TB cases 1, 4
The American Thoracic Society recommends treatment for patients initiating anti-TNF therapy or other biologics, patients preparing for organ or hematological transplantation, patients receiving dialysis for chronic renal failure, and patients with silicosis 1
The Centers for Disease Control and Prevention recommends treatment for children <5 years old with positive testing, and persons with radiographic evidence of prior untreated TB 4, 3

The European Respiratory Society emphasizes that active TB disease must be ruled out before initiating LTBI treatment, and chest radiography is mandatory to exclude active pulmonary TB 1, 5
The Centers for Disease Control and Prevention recommends assessing for TB symptoms, and obtaining sputum samples for acid-fast bacilli smear and culture if symptoms or abnormal chest X-ray are present 5

The World Health Organization and American Thoracic Society endorse multiple effective regimens, including isoniazid for 9 months, rifapentine plus isoniazid for 12 weeks, rifampin plus isoniazid for 3-4 months, and rifampin alone for 4 months 1, 2
The American Thoracic Society recommends isoniazid for 9 months as the only regimen for children 2

The European Respiratory Society requires monthly clinical monitoring for all patients, including assessing adherence to medication, reviewing symptoms of adverse drug reactions, and checking for hepatotoxicity symptoms 6, 3
The Centers for Disease Control and Prevention recommends routine monthly laboratory monitoring for high-risk patients, including those with HIV, liver disease, or alcohol use 4, 6

The Clinical Infectious Diseases society recommends that treatment is critical for HIV-infected patients, given a 7-10% annual reactivation risk, and that TST ≥5 mm is considered positive 2
The Praxis Medical Insights recommends baseline and ongoing laboratory monitoring for HIV-infected patients, and considering drug interactions with antiretroviral therapy, particularly rifampin 5

Before initiating any LTBI treatment, active TB disease must be definitively excluded through history, physical examination, chest radiography, and when indicated, bacteriologic studies, as recommended by the Centers for Disease Control and Prevention (CDC) 7, 8
The CDC recommends treating pregnant women at high risk for progression (HIV-infected or recent infection) with LTBI treatment, without delaying treatment during the first trimester 7, 8
For patients with radiographic evidence of prior untreated TB, or for HIV-infected persons, the CDC recommends using 9 months of isoniazid rather than 6 months 7, 8, 9

The American Thoracic Society recommends rifampin monotherapy for 4 months as the best option for patients who cannot tolerate isoniazid or pyrazinamide, with less hepatotoxicity and better compliance than isoniazid 7, 8
The CDC recommends rifampin + isoniazid for 3-4 months, with equivalent efficacy to 6-9 months isoniazid and better completion rates, requiring monitoring at weeks 2, 4, and 8 7, 8
For drug-resistant source cases, the CDC recommends isoniazid-resistant, rifampin-susceptible: rifampin + pyrazinamide for 2 months, or rifampin alone for 4 months, and multidrug-resistant (isoniazid + rifampin resistant): pyrazinamide + ethambutol or pyrazinamide + quinolone for 6-12 months 7, 8

The CDC recommends obtaining baseline liver function tests for HIV-infected patients, pregnant women, and patients with a history of chronic liver disease, and monthly clinical evaluations for isoniazid alone or rifampin alone regimens 7, 8
The American Thoracic Society recommends evaluations at weeks 2, 4, and 8 for rifampin + pyrazinamide regimens, and instructing patients to immediately stop treatment and seek medical evaluation if they develop signs of hepatotoxicity 7, 8

The CDC recommends never treating LTBI without first excluding active TB disease, obtaining chest X-ray and assessing for TB symptoms in all patients, and avoiding rifampin-pyrazinamide regimen routinely due to hepatotoxicity concerns 7, 8, 9
The American Thoracic Society recommends checking drug interactions, as rifampin significantly interacts with protease inhibitors and many other medications, and considering rifabutin substitution 8
The CDC recommends not using intermittent dosing without directly observed therapy, as twice or thrice weekly regimens must always be directly observed 7, 8, 9

For individuals exposed to MDR TB, a regimen of pyrazinamide combined with ethambutol or pyrazinamide combined with a fluoroquinolone administered for 6–12 months is recommended. This guidance is drawn from evidence reported in the American Journal of Respiratory and Critical Care Medicine (2000) 10.

In pregnant patients considered high‑risk (e.g., HIV‑infected or recent exposure), chest radiography should be performed even during the first trimester, using appropriate fetal shielding to minimize radiation exposure. This recommendation is based on findings published in the American Journal of Respiratory and Critical Care Medicine (2000) 11.